Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

November 25, 2022

Study Completion Date

November 25, 2022

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

CHF6001

CHF6001 will be administered using the NEXThaler® DPI device

Trial Locations (1)

1618

MC Comac Medical Ltd., Sofia

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY